Literature DB >> 3741470

Comparative intracellular uptake of adriamycin and 4'-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survival.

D J Kerr, A M Kerr, R I Freshney, S B Kaye.   

Abstract

4'-Deoxydoxorubicin (4'-deoxy) is a new adriamycin analogue with a similar spectrum of antitumour activity but is significantly more lipophilic than the parent compound. We report the kinetics and uptake of the two drugs by human non-small cell lung tumour cells in monolayer culture and the relationship between intracellular drug levels and cytotoxicity. The rate and degree of cell uptake of 4'-deoxy (Vmax = 30 ng/10(5) cells/min) was greater than that of adriamycin (Vmax = 0.15 ng/10(5) cells/min). Although for a given intracellular drug concentration adriamycin was more lethal, on the basis of extracellular drug concentration, cell kill was virtually identical. The log cell survival vs intracellular drug concentration plot was linear for adriamycin but biphasic for 4'-deoxy. Intracellular distribution of the two drugs was followed by fluorescent microscopy and it was apparent that adriamycin was localized mainly within the nucleus whereas 4'-deoxy accumulated within the cytoplasm. Our results suggest that the relationship between intracellular distribution of the two drugs could reflect different modes of action for the drugs with respect to binding sites or could be a non-specific phenomenon, unrelated to lethal effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3741470     DOI: 10.1016/0006-2952(86)90195-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  27 in total

1.  A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.

Authors:  A W El-Kareh; T W Secomb
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

2.  Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: computational modelling and preliminary in vivovalidation.

Authors:  Astrid Gasselhuber; Matthew R Dreher; Ari Partanen; Pavel S Yarmolenko; David Woods; Bradford J Wood; Dieter Haemmerich
Journal:  Int J Hyperthermia       Date:  2012       Impact factor: 3.914

3.  Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation.

Authors:  Astrid Gasselhuber; Matthew R Dreher; Ayele Negussie; Bradford J Wood; Frank Rattay; Dieter Haemmerich
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 4.  Transport of drugs from blood vessels to tumour tissue.

Authors:  Mark W Dewhirst; Timothy W Secomb
Journal:  Nat Rev Cancer       Date:  2017-11-10       Impact factor: 60.716

5.  Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes.

Authors:  S Oudard; A Thierry; T J Jorgensen; A Rahman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.

Authors:  J Cummings; I Meikle; J S Macpherson; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Longer heating duration increases localized doxorubicin deposition and therapeutic index in Vx2 tumors using MR-HIFU mild hyperthermia and thermosensitive liposomal doxorubicin.

Authors:  Chenchen Bing; Pratik Patel; Robert M Staruch; Sumbul Shaikh; Joris Nofiele; Michelle Wodzak Staruch; Debra Szczepanski; Noelle S Williams; Theodore Laetsch; Rajiv Chopra
Journal:  Int J Hyperthermia       Date:  2018-12-12       Impact factor: 3.914

8.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

9.  A tumor cord model for doxorubicin delivery and dose optimization in solid tumors.

Authors:  Steffen Eikenberry
Journal:  Theor Biol Med Model       Date:  2009-08-09       Impact factor: 2.432

10.  Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin.

Authors:  R Danesi; N Bernardini; C Agen; M Costa; L Zaccaro; D Pieracci; G Malvaldi; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.